Effects of Vildagliptin combined with Dapagliflozin in treatment of patients with newly diagnosed type 2 diabetes mellitus
Objective:To observe effects of Vildagliptin combined with Dapagliflozin in treatment of patients with newly diagnosed type 2 diabetes mellitus(T2DM).Methods:A prospective study was conducted on 62 newly diagnosed T2DM patients admitted to the hospital from March 2020 to April 2023.They were divided into study group and control group according to the random number table method,31 cases in each.Both groups were given diet and exercise guidance.On this basis,the control group was treated with Dapagliflozin orally,while the study group was treated with Vildagliptin on the basis of that of the control group.Both groups were treated for 2 months.The clinical efficacy,the levels of glucose and lipid metabolism indexes[fasting blood glucose(FBG),2 h postprandial blood glucose(2hPG),total cholesterol(TC)],the islet function indexes[fasting insulin(FINS),insulin resistance index(HOMA-IR)]levels,the serological indexes[adiponectin(APN),glucagon-like peptide-1(GLP-1)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 93.55%(29/31),which was higher than 74.19%(23/31)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FBG,2hPG,TC,FINS and HOMA-IR in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of GLP-1 and APN in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Vildagliptin combined with Dapagliflozin in the treatment of the newly diagnosed T2DM patients can improve the total effective rate of treatment and the levels of serological indexes,and reduce the levels of glucose and lipid metabolism indexes and islet function indexes.Moreover,it is superior to single Dapagliflozin treatment.
VildagliptinDapagliflozinNew diagnosisType 2 diabetes mellitusGlucose and lipid metabolismIslet functionAdverse reaction
NETL
NSTL
万方数据
